Company News

Dermatology Provider Ever/Body To Roll Out Its Own Skin Care Products

Will use $38M Series B to expand locations and offer its own prescription treatments.

Ever/Body, a company that calls itself a “cosmetic dermatology provider of personalized, tech-enabled services,” has raised $38 million in Series B funding, consisting of both venture equity and debt. 
The new funding will support Ever/Body's omni channel strategy, including market expansion, with the planned opening of multiple brick and mortar locations. 

In addition, the company says it will roll out a line of branded prescription dermatology products, aimed at addressing key concerns such as acne, hyperpigmentation, wrinkle reduction, rosacea and hair growth. 

Ever/Body currently offers professional treatments such as Botox fillers, Hydrafacial and Morpheus8 RF Microneedling, among others; via its website it sells products from SkinCeuticals and Supergoop.
The Series B funding was led by Tiger Global Management, an existing investor in the company. Additional investors include Addition, Fifth Wall, MetaProp, and Gaingels, and existing investors include Declaration Partners, ACME Capital and Redesign Health. 

This latest round of funding brings the company's total capital raised to date to $52 million.

Launched in September 2019, Ever/Body offers a tech-enabled consumer experience, curated menu of treatments, and tailored approach to each patient's unique, long-term skincare goals. Treatments are overseen by chief medical officer Dr. Jared Jagdeo and administered by a team of expert medical professionals. The company contends its two New York City locations have experienced accelerated growth, with strong patient retention and increased quarterly patient spend, despite the constraints of the pandemic.

“Ever/Body is a leader in the consumerization of healthcare, one of the most significant trends in retail today,” said Kevin Campos, Partner at Fifth Wall. “The cosmetic dermatology industry is ripe for innovation, and we believe Ever/Body's model, which combines deep medical expertise with technology, hospitality, and transparency, delivers a superior and more accessible consumer experience.”
“The aesthetics industry is experiencing exponential growth, proving massive potential in a market that's expected to increase at a compounded annual rate of 9.8% in the coming years,” said Amy Shecter, CEO of Ever/Body. “Ever/Body is poised to lead this growth by delivering personalized care that is far beyond the industry standard, made possible by our proprietary technology, training programs, and a highly-customized client experience.”

Keep up with the story. Subscribe to the Happi free daily

Related Breaking News